Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2726-2734

  Brunnemann, Anne Kathrin ^a   Bohn Wippert, Kathrin ^b   Zell, Roland ^b   Henke, Andreas ^b   Walther, Martin ^b   Braum, Oliver ^a,c   Maschkowitz, Gregor ^a   Fickenscher, Helmut ^a   Sauerbrei, Andreas ^b   Krumbholz, Andi ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Viramed Biotech AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMINO ACID; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; PENCICLOVIR; RECOMBINANT ENZYME; RECOMBINANT THYMIDINE KINASE; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; VIRUS ENZYME; RECOMBINANT PROTEIN; THYMIDINE KINASE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; EMBRYO; EN PASSANT MUTAGENESIS; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHENOTYPIC VARIATION; PRIORITY JOURNAL; STRAIN DIFFERENCE; STRAIN IDENTIFICATION; VARICELLA ZOSTER VIRUS; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HERPESVIRUS 3, HUMAN; HUMANS; RECOMBINANT PROTEINS; THYMIDINE KINASE;

EID: 84931291762     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05115-14     Document Type: Article

References (40)

1. Kempf W, Meylan P, Gerber S, Aebi C, Agosti R, Buchner S, Coradi B, Garweg J, Hirsch H, Kind C, Lauper U, Lautenschlager S, Reusser P, Ruef C, Wunderli W, Nadal D. 2007. Swiss recommendations for the management of varicella zoster virus infections. Swiss Med Wkly 137:239-251.
2. Au WY, Ma SY, Cheng VC, Ooi CG, Lie AK. 2003. Disseminated zoster, hyponatraemia, severe abdominal pain and leukaemia relapse: recognition of a new clinical quartet after bone marrow transplantation. Br J Dermatol 149:862-865. http://dx.doi.org/10.1046/j.1365-2133.2003.05656.x.
3. Choi WS, Kwon SS, Lee J, Choi SM, Lee JS, Eom JS, Sohn JW, Choeng HJ. 2014. Immunity and the burden of herpes zoster. J Med Virol 86:525-530. http://dx.doi.org/10.1002/jmv.23830.
4. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJ, Wallace MS, Wassilew SW, Whitley RJ. 2007. Recommendations for the management of herpes zoster. Clin Infect Dis 44(Suppl 1):S1-S26. http://dx.doi.org/10.1086/510206.
5. Sauerbrei A, Taut J, Zell R, Wutzler P. 2011. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 90:242-247. http://dx.doi.org/10.1016/j.antiviral.2011.04.005.
6. Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, Bialek SR, Marin M. 2014. Fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother 10:146-149. http://dx.doi.org/10.4161/hv.26200.
7. van der Beek MT, Vermont CL, Bredius RG, Marijt EW, van der Blij-de Brouwer CS, Kroes AC, Claas EC, Vossen AC. 2013. Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clin Infect Dis 56:335-343. http://dx.doi.org/10.1093/cid/cis879.
8. Chrisp P, Clissold SP. 1991. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
9. De Clercq E. 2004. Antiviral drugs in current clinical use. J Clin Virol 30:115-133. http://dx.doi.org/10.1016/j.jcv.2004.02.009.
10. Sahli R, Andrei G, Estrade C, Snoeck R, Meylan PR. 2000. A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame. Antimicrob Agents Chemother 44:873-878. http://dx.doi.org/10.1128/AAC.44.4.873-878.2000.
11. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC. 2008. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3:e1638. http://dx.doi.org/10.1371/journal.pone.0001638.
12. Domi A, Moss B. 2002. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci USA99:12415-12420. http://dx.doi.org/10.1073/pnas.192420599.
13. Meyer C, Dewane J, Haberthur K, Engelmann F, Arnold N, Gray W, Messaoudi I. 2013. Bacterial artificial chromosome derived simian varicella virus is pathogenic in vivo. Virol J 10:278. http://dx.doi.org/10.1186/1743-422X-10-278.
14. Nagel CH, Pohlmann A, Sodeik B. 2014. Construction and characterization of bacterial artificial chromosomes (BACs) containing herpes simplex virus full-length genomes. Methods Mol Biol 1144:43-62. http://dx.doi.org/10.1007/978-1-4939-0428-0-4.
15. Wussow F, Fickenscher H, Tischer BK. 2009. Red-mediated transposition and final release of the mini-F vector of a cloned infectious herpesvirus genome. PLoS One 4:e8178. http://dx.doi.org/10.1371/journal.pone.0008178.
16. Tischer BK, von Einem J, Kaufer B, Osterrieder N. 2006. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197. http://dx.doi.org/10.2144/000112096.
17. Fillet AM, Dumont B, Caumes E, Visse B, Agut H, Bricaire F, Huraux JM. 1998. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Virol 55:250-254.
18. Saint-Léger E, Caumes E, Breton G, Douard D, Saiag P, Huraux JM, Bricaire F, Agut H, Fillet AM. 2001. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 33:2061-2067. http://dx.doi.org/10.1086/324503.
19. Bleymehl K, Cinatl J, Schmidt-Chanasit J. 2011. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet. Med Microbiol Immunol 200:193-202. http://dx.doi.org/10.1007/s00430-011-0191-4.
20. Sauerbrei A, Zell R, Harder M, Wutzler P. 2006. Genotyping of different varicella vaccine strains. J Clin Virol 37:109-117. http://dx.doi.org/10.1016/j.jcv.2006.07.002.
21. Kress M, Fickenscher H. 2001. Infection by human varicella-zoster virus confers norepinephrine sensitivity to sensory neurons from rat dorsal root ganglia. FASEB J 15:1037-1043. http://dx.doi.org/10.1096/fj.00-0440com.
22. Sauerbrei A, Liermann K, Bohn K, Henke A, Zell R, Gronowitz S, Wutzler P. 2012. Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res 96:105-107. http://dx.doi.org/10.1016/j.antiviral.2012.08.001.
23. Tischer BK, Kaufer BB, Sommer M, Wussow F, Arvin AM, Osterrieder N. 2007. A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol 81:13200-13208. http://dx.doi.org/10.1128/JVI.01148-07.
24. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol 634:421-430. http://dx.doi.org/10.1007/978-1-60761-652-8-30.
25. Sauerbrei A, Philipps A, Zell R, Wutzler P. 2007. Genotyping of varicella-zoster virus strains after serial passages in cell culture. J Virol Methods 145:80-83. http://dx.doi.org/10.1016/j.jviromet.2007.05.004.
26. Schubert A, Gentner E, Bohn K, Schwarz M, Mertens T, Sauerbrei A. 2014. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res 107:16-22. http://dx.doi.org/10.1016/j.antiviral.2014.03.015.
27. Morfin F, Thouvenot D. 2003. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 26:29-37. http://dx.doi.org/10.1016/S1386-6532(02)00263-9.
28. Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, Kessler HA, Landry B, Mills J. 1991. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 325:551-555.
29. Tyler SD, Peters GA, Grose C, Severini A, Gray MJ, Upton C, Tipples GA. 2007. Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology 359:447-458. http://dx.doi.org/10.1016/j.virol.2006.09.037.
30. Hawrami K, Breuer J. 1999. Development of a fluorogenic polymerase chain reaction assay (TaqMan) for the detection and quantitation of varicella zoster virus. J Virol Methods 79:33-40. http://dx.doi.org/10.1016/S0166-0934(98)00176-1.
31. Tischer BK, Kaufer BB. 2012. Viral bacterial artificial chromosomes: generation, mutagenesis, and removal of mini-F sequences. J Biomed Biotechnol 2012:472537. http://dx.doi.org/10.1155/2012/472537.
32. Wussow F, Spieckermann T, Brunnemann A, Hüske L, Toptan T, Fickenscher H. 2011. Bacterial genetics of large mammalian DNA viruses: bacterial artificial chromosomes as a prerequisite for efficiently studying virus DNA replication and functions, p 669-694. In Seligmann H (ed), DNA replication: current advances. Intech, Rijeka, Croatia.
33. Drouot E, Piret J, Boivin G. 2013. Novel method based on "en passant" mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J Clin Microbiol 51:3216-3224. http://dx.doi.org/10.1128/JCM.01275-13.
34. Hantz S, Cotin S, Borst E, Couvreux A, Salmier A, Garrigue I, Merville P, Mengelle C, Attal M, Messerle M, Alain S. 2013. Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. Antiviral Res 98:130-134. http://dx.doi.org/10.1016/j.antiviral.2013.02.002.
35. Zhang Z, Selariu A, Warden C, Huang G, Huang Y, Zaccheus O, Cheng T, Xia N, Zhu H. 2010. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog 6:e1000971. http://dx.doi.org/10.1371/journal.ppat.1000971.
36. Fillet AM, Visse B, Caumes E, Dumont B, Gentilini M, Huraux JM. 1995. Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis 21:1348-1349. http://dx.doi.org/10.1093/clinids/21.5.1348.
37. Chevillotte M, von Einem J, Meier BM, Lin FM, Kestler HA, Mertens T. 2010. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res 85:318-327. http://dx.doi.org/10.1016/j.antiviral.2009.10.004.
38. Andrei G, Topalis D, Fiten P, McGuigan C, Balzarini J, Opdenakker G, Snoeck R. 2012. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol 86:2641-2652. http://dx.doi.org/10.1128/JVI.06620-11.
39. Stoelben S, Arns W, Renders L, Hummel J, Muhlfeld A, Stangl M, Fischereder M, Gwinner W, Suwelack B, Witzke O, Durr M, Beelen DW, Michel D, Lischka P, Zimmermann H, Rubsamen-Schaeff H, Budde K. 2014. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 27:77-86. http://dx.doi.org/10.1111/tri.12225.
40. Vere Hodge RA, Field HJ. 2013. Antiviral agents for herpes simplex virus. Adv Pharmacol 67:1-38. http://dx.doi.org/10.1016/B978-0-12-405880-4.00001-9.